Loading
A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments is a phase 1/2 interventional study registered as NCT06799637 by Evopoint Biosciences Inc., with 350 participants planned, started 2023-12-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: XNW28012.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Evopoint Biosciences, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Evopoint Biosciences and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/